Pathway
Defective pyroptosis
Pyroptosis is a form of lytic inflammatory programmed cell death that is mediated by the pore‑forming gasdermins (GSDMs) (Shi J et al. 2017) to stimulate immune responses through the release of pro‑inflammatory interleukin (IL)‑1β, IL‑18 (mainly in GSDMD-mediated pyroptosis) as well as danger signals such as adenosine triphosphate (ATP) or high mobility group protein B1 (HMGB1) (reviewed in Shi J et al. 2017; Man SM et al. 2017; Tang D et al. 2019; Lieberman J et al. 2019). Pyroptosis protects the host from microbial infection but can also lead to pathological inflammation if overactivated or dysregulated (reviewed in Orning P et al. 2019; Tang L et al. 2020). During infections, the excessive production of cytokines can lead to a cytokine storm, which is associated with acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS) (reviewed in Tisoncik JR et al. 2012; Karki R et al. 2020; Ragab D et al. 2020). Pyroptosis has a close but complicated relationship to tumorigenesis, affected by tissue type and genetic background. Pyroptosis can trigger potent antitumor immune responses or serve as an effector mechanism in antitumor immunity (Wang Q et al. 2020; Zhou Z et al. 2020; Zhang Z et al. 2020), while in other cases, as a type of proinflammatory death, pyroptosis can contribute to the formation of a microenvironment suitable for tumor cell growth (reviewed in Xia X et al. 2019; Jiang M et al. 2020; Zhang Z et al. 2021).
Continue reading
This Reactome module describes the defective GSDME function caused by cancer‑related GSDME mutations (Zhang Z et al. 2020). It also shows epigenetic inactivation of GSDME due to hypermethylation of the GSDME promoter region (Akino K et al. 2007; Kim MS et al. 2008a,b; Croes L et al. 2017, 2018; Ibrahim J et al. 2019). Aberrant promoter methylation is considered to be a hallmark of cancer (Ehrlich M et al. 2002; Dong Y et al. 2014; Lam K et al. 2016; Croes L et al. 2018). Treatment with the DNA methyltransferase inhibitor decitabine (5‑aza‑2'‑deoxycytidine or DAC) may elevate GSDME expression in certain cancer cells (Akino K et al. 2007; Fujikane T et al. 2009; Wang Y et al. 2017).
What the reference databases state
Statements
39 statements
39 statements · 1 reference database · Subject: Defective pyroptosis · Sources: Reactome
- DNMT1 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- DNMT3A participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- DNMT3B participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- EED participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- EZH2 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- GSDME participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2AB1 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2AC14 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2AC18; H2AC19 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2AC20 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2AC4; H2AC8 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2AC6 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
Show the remaining 27
- H2AC7 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2AJ participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2AX participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2AZ2 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC1 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC11 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC12 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC13 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC14 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC15 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC17 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC21 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC26 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC3 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC4; H2BC6; H2BC7; H2BC8; H2BC10 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H2BC9 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H3-3A; H3-3B participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H3C15; H3C14; H3C13 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- POLA1 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- POLA2 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- PRIM1 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- PRIM2 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- RBBP4 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- RBBP7 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only
- SUZ12 participates in Defective pyroptosisProteinReactome R-HSA-9710421Inferred only